Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Darmstadt – page 117

1 664 clinical trials in Darmstadt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Darmstadt at a glance
1 664
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 664 trials in Darmstadt

Open in trial search

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Fabry's disease

Not recruiting

Study of venglustat tablets to reduce neuropathic and abdominal pain in patients aged 16 and older with Fabry disease who are untreated or haven't received treatment for 6 months

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Venglustat
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Afatinib and Osimertinib for Patients with EGFR-Mutated, T790M Negative Non-Squamous Non-Small Cell Lung Cancer in First-Line Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Afatinib
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Study on the Safety of Osimertinib with Radiation for Patients with Stage IV EGFR-Mutation Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AIO-Studien gGmbH

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Myasthenia gravis

Not recruiting

Study on the Effects of Iptacopan in Patients with Generalized Myasthenia Gravis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study of Cabozantinib and Avelumab for Patients with Advanced Neuroendocrine Tumors G3 Resistant to Standard Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Study of Cemiplimab Compared to Placebo After Surgery and Radiation for Patients with High-Risk Skin Squamous Cell Carcinoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Hypertension

Not recruiting

Study on the Effectiveness of Ethanol in Treating Hypertension in Patients with Uncontrolled High Blood Pressure

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ethanol, Anhydrous
  • Sponsor:Ablative Solutions Inc.

Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dimethyl Fumarate
  • Sponsor:Novartis Pharma AG

Endometrial cancer+5

Not recruiting

A Phase 1/2a Study of BNT142 Safety and Early Effectiveness in Patients with Advanced Solid Tumors Expressing CLDN6 Protein

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:BioNTech SE

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Darmstadt

What the registry says about research in the country

01 Dermatology Studies

Extensive research focusing on plaque psoriasis and hidradenitis suppurativa, evaluating new therapeutic approaches for chronic skin conditions. Multiple trials are testing novel treatments for moderate to severe cases.

  • Psoriasis Management
  • Hidradenitis Suppurativa Treatment
  • Atopic Dermatitis Therapy

Several innovative compounds being tested including ESK-001, remibrutinib, and JNJ-77242113.

02 Respiratory Medicine

Comprehensive studies addressing severe asthma and COPD, with particular attention to treatments for patients with eosinophilic phenotypes and those requiring advanced care options.

  • Asthma Control
  • COPD Management
  • Chronic Cough Treatment

Trials evaluating new inhalation therapies and biological treatments for better disease control.

03 Oncology Research

Advanced studies in acute myeloid leukemia, investigating combination therapies for patients ineligible for intensive chemotherapy. Focus on targeted treatments for specific genetic mutations.

  • AML Treatment
  • Novel Drug Combinations
  • Targeted Therapies

Investigating innovative approaches including revumenib in combination with established treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.